COMBI-TED, NCT04884282 / 2020-005170-10: Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) |
|
|
| Recruiting | 2 | 105 | Europe | Tedopi, Nivolumab, Docetaxel | Fondazione Ricerca Traslazionale, Bristol Myer Squibb International Corporation, OSE Immunotherapeutics | Metastatic Non Small Cell Lung Cancer | 10/23 | 05/25 | | |
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients |
|
|
| Active, not recruiting | 2 | 31 | Europe | Abemaciclib, Aromatase Inhibitors | University of Milano Bicocca | Advanced Breast Cancer | 12/23 | 12/23 | | |
